UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

SIOG COVID-19 Working Group recommendations on COVID-19 therapeutic approaches in older adults with cancer

Journal of geriatric oncology, 2023-07, Vol.14 (6), p.101564-101564, Article 101564

2023

Volltextzugriff (PDF)

Metastatic Prostate cancer (MPCa) is characterized by heterogeneous management. Multiple treatment options increases decisions generation and reasons for treatment selection are not yet elucidated, especially for elderly patients

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S13

2022

Volltextzugriff (PDF)

Prospective study to evaluate the role of geriatric assesment (GA) in patients with stage III unresectable non small cell lung cancer (NSCLC)

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S63

2022

Volltextzugriff (PDF)

SIOG2022-0029 - Descriptive analysis of loss of opportunity for elderly cancer patients due to the COVID-19 pandemic

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S73-S73

2022

Volltextzugriff (PDF)

Descriptive analysis of loss of opportunity for elderly cancer patients due to the COVID-19 pandemic

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S73-S73

2022

Volltextzugriff (PDF)

SIOG2022-0148 - Metastatic Prostate cancer (MPCa) is characterized by heterogeneous management. Multiple treatment options increases decisions generation and reasons for treatment selection are not yet elucidated, especially for elderly patients

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S13-S13

2022

Volltextzugriff (PDF)

SIOG2022-0146 - Oncogeriatric Consultation. Experience of our Section

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S64-S65

2022

Volltextzugriff (PDF)

Oncogeriatric Consultation. Experience of our Section

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S64-S65

2022

Volltextzugriff (PDF)

SIOG2022-0149 - Analysis of COVID infection during the pandemic in a medical oncology section: comparison between elderly and young patients

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S74-S74

2022

Volltextzugriff (PDF)

SIOG2022-0132 - Prospective study to evaluate the role of geriatric assesment (GA) in patients with stage III unresectable non small cell lung cancer (NSCLC)

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S63-S63

2022

Volltextzugriff (PDF)

Analysis of COVID infection during the pandemic in a medical oncology section: comparison between elderly and young patients

Journal of geriatric oncology, 2022-10, Vol.13 (8), p.S74

2022

Volltextzugriff (PDF)

Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer

Clinical & translational oncology, 2022-06, Vol.24 (6), p.1033-1046

2022

Volltextzugriff (PDF)

SIOG2021-0039 - Use of geriatric assessment (GA) in metastatic castration-resistant prostate cancer (MCRPC) in elderly cancer patients suitable for docetaxel

Journal of geriatric oncology, 2021-12, Vol.12 (8), p.S46-S46

2021

Volltextzugriff (PDF)

Use of geriatric assessment (GA) in metastatic castration-resistant prostate cancer (MCRPC) in elderly cancer patients suitable for docetaxel

Journal of geriatric oncology, 2021-12, Vol.12 (8), p.S46

2021

Volltextzugriff (PDF)

Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e16542-e16542

2021

Volltextzugriff (PDF)

640P Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel

Annals of oncology, 2020-09, Vol.31, p.S526-S526

2020

Volltextzugriff (PDF)

1317P Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting

Annals of oncology, 2020-09, Vol.31, p.S851-S851

2020

Volltextzugriff (PDF)

1578P COVID-19 and hospitalised cancer patients: Now it’s time for patients to talk

Annals of oncology, 2020-09, Vol.31, p.S959-S959

2020

Volltextzugriff (PDF)

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5008-5008

2020

Volltextzugriff (PDF)

Use of Tachosil® as an adjuvant therapeutic option in neurotrophic keratopathy in order to prevent perforation

Indian journal of ophthalmology, 2019-07, Vol.67 (7), p.1198-1200

2019

Volltextzugriff (PDF)

2 - Alimentation au biberon

Alimentation de l’enfant de 0 à 3 ans, 2017, p.19-41

Third Edition, 2017

Volltextzugriff (PDF)

5 - Prise en charge diététique de certaines pathologies

Alimentation de l’enfant de 0 à 3 ans, 2017, p.97-116

Third Edition, 2017

Volltextzugriff (PDF)

Annexes

Alimentation de l’enfant de 0 à 3 ans, 2017, p.117-204

Third Edition, 2017

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(56)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SIOG COVID-19 Working Group recommendations on COVID-19 therapeutic approaches in older adults with cancer

Metastatic Prostate cancer (MPCa) is characterized by heterogeneous management. Multiple treatment options increases decisions generation and reasons for treatment selection are not yet elucidated, especially for elderly patients

Prospective study to evaluate the role of geriatric assesment (GA) in patients with stage III unresectable non small cell lung cancer (NSCLC)

SIOG2022-0029 - Descriptive analysis of loss of opportunity for elderly cancer patients due to the COVID-19 pandemic

Descriptive analysis of loss of opportunity for elderly cancer patients due to the COVID-19 pandemic

SIOG2022-0148 - Metastatic Prostate cancer (MPCa) is characterized by heterogeneous management. Multiple treatment options increases decisions generation and reasons for treatment selection are not yet elucidated, especially for elderly patients

SIOG2022-0146 - Oncogeriatric Consultation. Experience of our Section

Oncogeriatric Consultation. Experience of our Section

SIOG2022-0149 - Analysis of COVID infection during the pandemic in a medical oncology section: comparison between elderly and young patients

SIOG2022-0132 - Prospective study to evaluate the role of geriatric assesment (GA) in patients with stage III unresectable non small cell lung cancer (NSCLC)

Analysis of COVID infection during the pandemic in a medical oncology section: comparison between elderly and young patients

Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer

SIOG2021-0039 - Use of geriatric assessment (GA) in metastatic castration-resistant prostate cancer (MCRPC) in elderly cancer patients suitable for docetaxel

Use of geriatric assessment (GA) in metastatic castration-resistant prostate cancer (MCRPC) in elderly cancer patients suitable for docetaxel

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

Lenvatinib in Combination With Pembrolizumab in Patients with Treatment-Naïve and Treatment-Experienced Metastatic Renal Cell Carcinoma: Results From a Phase 1b/2 Study

Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial

640P Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel

1317P Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting

1578P COVID-19 and hospitalised cancer patients: Now it’s time for patients to talk

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)

Use of Tachosil® as an adjuvant therapeutic option in neurotrophic keratopathy in order to prevent perforation

2 - Alimentation au biberon

5 - Prise en charge diététique de certaines pathologies

Annexes

Suchergebnisse filtern